Xenon Pharmaceuticals (XENE) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 2, 2026, to be held virtually for shareholders of record as of April 7, 2026.

• Shareholders are encouraged to review proxy materials online and may request paper copies if desired.

Voting matters and shareholder proposals

• Shareholders will vote to receive 2025 financial statements and auditor's report.

• Election of eight director nominees for a one-year term is on the agenda.

• Advisory vote on executive compensation and on the frequency of future say-on-pay votes.

• Approval of the 2026 Equity Incentive Plan is proposed.

• Appointment of PricewaterhouseCoopers LLP as auditor and authorization for the Audit Committee to set auditor remuneration.

Board of directors and corporate governance

• Eight director nominees are listed for election, each to serve until the next annual meeting or until successors are elected.